Healthcare - Biotechnology - NASDAQ - US
$ 3.8
-11.6 %
$ 122 M
Market Cap
-2.24
P/E
BALANCE SHEET
41.2 M
ASSETS
28.5 M
LIABILITIES
12.7 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Candel Therapeutics, Inc.
| Current Assets | 36.8 M |
| Cash & Short-Term Investments | 35.4 M |
| Receivables | 0 |
| Other Current Assets | 1.38 M |
| Non-Current Assets | 4.4 M |
| Long-Term Investments | 0 |
| PP&E | 4.02 M |
| Other Non-Current Assets | 382 K |
| Current Liabilities | 14.2 M |
| Accounts Payable | 422 K |
| Short-Term Debt | 9.92 M |
| Other Current Liabilities | 3.84 M |
| Non-Current Liabilities | 14.3 M |
| Long-Term Debt | 13.4 M |
| Other Non-Current Liabilities | 916 K |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| ASSETS | |||||
| Cash & Cash Equivalents | 35.4 | 70.1 | 82.6 | 35.1 | 5.2 |
| Short Term Investments | 0 | 0 | 0 | 0 | 39.9 |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.4 | 1.9 | 4.6 | 93 K | 0.2 |
| Total Current Assets | 36.8 | 71.9 | 84.9 | 35.1 | 45.2 |
| PP&E | 4.0 | 5.5 | 3.8 | 2.8 | 0.4 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0.3 | 0.4 | 0.3 | 0.3 |
| Other Long Term Assets | 0.4 | 0.3 | 0 | 83 K | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 41.2 | 77.7 | 89.2 | 38.3 | 45.9 |
| LIABILITIES | |||||
| Accounts Payable | 0.4 | 0.4 | 1.6 | 0.9 | 0.2 |
| Short Term Debt | 9.9 | 0.9 | 0 | 0.5 | 0 |
| Other Current Liabilities | 3.8 | 4.3 | 3.8 | 3.3 | 1.2 |
| Total Current Liabilities | 14.2 | 5.6 | 5.4 | 4.7 | 1.4 |
| Long Term Debt | 13.4 | 22.3 | 0.6 | 0.5 | 0.4 |
| Deferred Tax Income | 0 | 0.8 | 0 | 0 | 0 |
| Other Liabilities | 0.9 | 1.9 | 19.1 | 56.5 | 51.9 |
| Total Liabilities | 28.5 | 30.0 | 25.1 | 61.8 | 53.9 |
| EQUITY | |||||
| Common Stock | 0.3 | 0.3 | 0.3 | 0.1 | 0.1 |
| Retained Earnings | (137.0) | (99.1) | (80.3) | (44.2) | (26.5) |
| Other Accumulative Comprehensive Income/Loss | 0 | 0 | (89.2) | (49.1) | 19 K |
| Total Equity | 12.7 | (99.1) | 64.1 | (23.6) | (8.0) |
| Total Liabilities and Equity | 41.2 | (69.1) | 89.2 | 38.3 | 45.9 |
| SHARES OUTSTANDING | |||||
| Common Shares Outstanding | 28.9 | 28.8 | 28.7 | 29.1 | 29.1 |